Patrizia Cavazzoni was the head of the FDA’s Center for Drug Evaluation and Research, from 2020 until her departure in January. FDA. By Matthew Herper. Feb. 24, 2025.

The FDA’s influential director of the Center for Drug Evaluation and Research, Patrizia Cavazzoni, M.D., will soon retire from the agency. The seven-year FDA veteran communicated the decision in ...

Patrizia Cavazzoni, leader of the FDA's Center for Drug Evaluation and Research, is leaving the agency on Jan. 18.

Patrizia Cavazzoni, ... Cavazzoni led the FDA’s Center for Drug Evaluation and Research from 2021 until her departure in mid-January. She was one of several top officials, ...

Feb 24 (Reuters) - Pfizer (PFE.N), opens new tab on Monday named the former head of the U.S. health regulator's drug evaluation unit, Patrizia Cavazzoni, as its chief medical officer, bringing ...

Pfizer (NYSE:PFE) has tapped Patrizia Cavazzoni, the former head of drug regulation at the FDA, as its new chief medical officer. Cavazzoni was most recently director of the Center for Drug ...

The US Food and Drugs Administration (FDA) has confirmed that its director of the Centre for Drug Evaluation and Research (CDER), Patrizia Cavazzoni, has announced her resignation ahead of Donald ...

"It is the FDA's role to ensure that drugs are safe and effective," said Dr. Patrizia Cavazzoni, director of the FDA's Center for Drug Evaluation and Research, in a news release on Thursday.

"It is the FDA’s role to ensure that drugs are safe and effective," Patrizia Cavazzoni, director of the FDA’s Center for Drug Evaluation and Research, said in a statement.

FDA announces common ... in the process to propose removing oral phenylephrine because it is not effective as a nasal decongestant,” said Dr. Patrizia Cavazzoni, director of the FDA’s ...

Pfizer has appointed former Patrizia Cavazzoni, MD, former director of the FDA’s Center for Drug Evaluation and Research, as its new chief medical officer, Bloomberg reported Feb. 24.